Michael Y. Choi, MD

Moores Cancer Center, University of California San Diego

N/A

Poster(s):

• 1115 - Venetoclax Consolidation after BTKi Based Therapy for Patients with CLL

• 2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies

• 2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.